RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer
{{output}}
Targeted therapy has achieved significant success in the treatment of non-small cell lung cancer (NSCLC), particularly in patients harboring common oncogenic driver mutations such as EGFR, KRAS, and ALK rearrangement. However, ~35-50% of NSCLC patients without... ...
